Eledon Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $245.44M
- P/E (TTM)
- –
- Dividend yield
- –
About Eledon Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company that develops immunomodulatory therapies targeting the CD40 Ligand pathway. Its primary investigational product candidate is tegoprubart, an antibody designed to block CD40L signaling to suppress immune responses and promote immune tolerance without causing lymphocyte depletion or platelet activation. The company focuses on developing treatments to prevent organ rejection in both human-to-human allograft and animal-to-human xenograft transplantation, especially kidney transplants, as well as therapies for amyotrophic lateral sclerosis. As a clinical-stage development company without approved commercial products, its end users are intended to be transplant recipients and individuals with neurodegenerative conditions.
The company operates within the United States and conducts business across a single operating segment dedicated to pharmaceutical research and clinical development. It relies on external contract research organizations and third-party manufacturers to carry out testing and produce candidate materials. The company maintains its principal executive offices in Irvine, California.
Summary of the business section of Eledon Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Eledon Pharmaceuticals, Inc.
- Headquarters
- Irvine, CA
- Address
- 19800 Macarthur Blvd., Suite 250 92612
- Phone
- (949) 238-8090
- Website
- eledon.com
- Employees
- 33, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Crowe LLP, Los Angeles, California
Stock & identifiers
- Ticker
- ELDN
- Exchange
- Nasdaq
- IPO date
- Sep 18, 2014
- Shares outstanding
- 81M, Aug 10, 2026
- Public float
- $145.17M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-18 reverse, Nov 16, 2020; 1-for-18 reverse, Oct 5, 2020; 1-for-291 reverse, Aug 9, 2017; 1-for-9 reverse, May 11, 2017
- SEC CIK
- 1404281
- CUSIP
- 28617K101
- ISIN
- US28617K1016
- LEI
- 549300S17CAM13O43606
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven Perrin | President, Director | 153,353 |
| David-Alexandre C. Gros | Chief Executive Officer, Director | 363,454 |
| Bryan E. Smith | General Counsel, Corporate Sec | – |
| Paul Sean Little | Chief Financial Officer | 10,000 |
| James A. Robinson Jr. | Director | 3,430 |
| John S. McBride | Director | 3,430 |
| Keith Katkin | Director | 8,575 |
| June Lee | Director | 3,430 |
| Jan Hillson | Director | 3,430 |
| Allan Kirk | Director | 3,430 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Gros | $3.22M | -$315.00K | $1.64M | $66 | – |
| FY2024 Dr. Gros | $5.64M | $6.79M | $3.83M | $181 | – |
| FY2023 Dr. Gros | $2.55M | $404.58K | $1.43M | $79 | – |
| FY2022 Dr. Gros | $1.12M | -$1.98M | $1.05M | $52 | – |
| FY2021 Dr. Gros | $747.50K | -$4.79M | $2.06M | $29 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 13, 2026, Eledon had 33 employees, all of whom are full-time.”
Corporate history
Events identified from SEC filings